Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Are Insulin Mimetics Protective Against Comorbidity in Patients With Neuro-Autoimmune Disease?
Autoimmune Neurology
P10 - Poster Session 10 (8:00 AM-9:00 AM)
6-016
IM are used to treat patients with diabetes mellitus (DM) and have been shown to protect against progressive neurological damage. Despite their neuroprotective benefits, the extent of their neuroprotection in patients with NAD has not been completely characterized. 
To investigate the neuroprotective potential of insulin mimetics (IM) in patients with neuro autoimmune disease (NAD) and high risk comorbidities. 
A retrospective analysis on 34464 patients hospitalized at a tertiary care center in a major metropolitan area was conducted. 168 patients were taking IM medications. 7848 patients were taking medicine other than IM for their DM (nIM). 7690 patients were taking insulin without IM medications. 26448 patients were not on any DM medication (nDM). The outcomes compared included the prevalence of NAD, diabetic neuropathy and/or retinopathy (DMNR), and the prevalence of high risk comorbidities defined as those with either heart failure, chronic kidney disease, stroke, or encephalopathy. 
The prevalence of NAD was 0.6%, 0.52%, 0.53%, 0.56% among patients in the IM, nIM, insulin, and nDM groups respectively (p>0.05). 19.5% of NAD and 23.6% of those without NAD had high risk comorbidities (p>0.05). Among those with autoimmune disease, 31% of those taking any diabetic medication and 16% of nDM had high risk comorbidities (p>0.05). The prevalence of DMNR was 10% and 8% in IM and nIM groups respectively (p>0.05).
These results suggest that IM medications may benefit patients with NAD against additional comorbidity as those without NAD and DM are expected to have less high risk disease. However, more studies are needed to determine whether IM medications play a role in neuro-autoimmune disease progression and mortality.
Authors/Disclosures
Mohsen Ahmed (New Jersey Medical school)
PRESENTER
Mr. Ahmed has nothing to disclose.
Umair Azhar Mr. Azhar has nothing to disclose.
Nabeel Ahmed (Stony Brook University Hospital) Mr. Ahmed has nothing to disclose.
Afaaq Ahmed Mr. Ahmed has nothing to disclose.
Sania Azhar Ms. Azhar has nothing to disclose.
Nizar Souayah, MD, FAAN (NJMS) Dr. Souayah has received publishing royalties from a publication relating to health care.